These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35818154)

  • 1. Accelerated/rush allergen immunotherapy.
    Greiwe J; Bernstein JA
    Allergy Asthma Proc; 2022 Jul; 43(4):344-349. PubMed ID: 35818154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy.
    Quiralte J; Justicia JL; Cardona V; Dávila I; Moreno E; Ruiz B; García MA
    Immunotherapy; 2013 Dec; 5(12):1295-303. PubMed ID: 24283840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerated immunotherapy schedules.
    Calabria CW
    Curr Allergy Asthma Rep; 2013 Aug; 13(4):389-98. PubMed ID: 23728613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of allergen immunotherapy in North America from 2008-2017: Lessons learned from the ACAAI/AAAAI National Surveillance Study of adverse reactions to allergen immunotherapy.
    Bernstein DI; Epstein TEG
    Allergy Asthma Proc; 2020 Mar; 41(2):108-111. PubMed ID: 32122446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of subcutaneous allergen immunotherapy.
    Bernstein DI; Epstein TG
    Allergy Asthma Proc; 2022 Jul; 43(4):267-271. PubMed ID: 35818150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated immunotherapy schedules: review of efficacy and safety.
    Cox L
    Ann Allergy Asthma Immunol; 2006 Aug; 97(2):126-37; quiz 137-40, 202. PubMed ID: 16937741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The local and systemic side-effects of venom and inhaled-allergen subcutaneous immunotherapy.
    Adamic K; Zidarn M; Bajrovic N; Erzen R; Kopac P; Music E
    Wien Klin Wochenschr; 2009; 121(9-10):357-60. PubMed ID: 19562302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of subcutaneous immunotherapy with inhalant allergen extracts: a single-center 30-year experience from Turkey.
    Kartal O; Gulec M; Caliskaner Z; Musabak U; Sener O
    Immunopharmacol Immunotoxicol; 2015 Jun; 37(3):280-6. PubMed ID: 25858053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AAAAI and ACAAI surveillance study of subcutaneous immunotherapy, Year 3: what practices modify the risk of systemic reactions?
    Epstein TG; Liss GM; Murphy-Berendts K; Bernstein DI
    Ann Allergy Asthma Immunol; 2013 Apr; 110(4):274-8, 278.e1. PubMed ID: 23535092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for fatal and nonfatal reactions to immunotherapy (2008-2018): postinjection monitoring and severe asthma.
    Epstein TG; Murphy-Berendts K; Liss GM; Bernstein DI
    Ann Allergy Asthma Immunol; 2021 Jul; 127(1):64-69.e1. PubMed ID: 33753219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allergen immunotherapy for respiratory allergy: to what extent can the risk of systemic reactions be reduced?
    Incorvaia C; Pucciarini F; Makri E; Gritti BL; Ridolo E
    Expert Opin Drug Saf; 2020 Jul; 19(7):843-848. PubMed ID: 32511028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rush immunotherapy: experience with a one-day schedule.
    Sharkey P; Portnoy J
    Ann Allergy Asthma Immunol; 1996 Feb; 76(2):175-80. PubMed ID: 8595538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous Immunotherapy Safety: Incidence per Surveys and Risk Factors.
    Sánchez-Borges M; Bernstein DI; Calabria C
    Immunol Allergy Clin North Am; 2020 Feb; 40(1):25-39. PubMed ID: 31761119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Birch Pollen Preparation.
    Buczyłko K; van der Werf JF; Boot D; van Ree R
    Int Arch Allergy Immunol; 2017; 172(3):183-186. PubMed ID: 28380494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of allergen-specific immunotherapy (desensitization) for the treatment of allergies in Germany. Current situation].
    Kleine-Tebbe J; Ackermann-Simon J; Hanf G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 Mar; 55(3):343-50. PubMed ID: 22373847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated immunotherapy schedules and premedication.
    Calabria CW; Cox L
    Immunol Allergy Clin North Am; 2011 May; 31(2):251-63, ix. PubMed ID: 21530818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and adverse reactions to subcutaneous immunotherapy in children with allergic rhinitis/asthma.
    Duman Senol H; Topyildiz E; Ekici B; Gulen F; Demir E
    Int J Pediatr Otorhinolaryngol; 2022 Nov; 162():111292. PubMed ID: 36007303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study.
    Cardona R; Lopez E; Beltrán J; Sánchez J
    Allergol Immunopathol (Madr); 2014; 42(2):90-5. PubMed ID: 23265265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Safety Profiles of 3 Different Hymenoptera Venom Immunotherapy Protocols: A Retrospective 2-Center Study of 143 Patients.
    Pospischil IM; Kagerer M; Cozzio A; Angelova-Fischer I; Guenova E; Ballmer-Weber B; Hoetzenecker W
    Int Arch Allergy Immunol; 2020; 181(10):783-789. PubMed ID: 32781451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and adverse reactions in subcutaneous allergen immunotherapy: a review.
    Incorvaia C; Cavaliere C; Schroeder JW; Leo G; Nicoletta F; Barone A; Ridolo E
    Acta Biomed; 2023 Aug; 94(4):e2023172. PubMed ID: 37539607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.